How much less Irish people drank while taking weight loss drugs like Ozempic: study
Talk about a lucky charm.
Drugs like Ozempic — which mimic the appetite-suppressing GLP-1 hormone the body naturally produces after eating — have been shown to spur weight loss as well as ease knee osteoarthritis pain, calm skin conditions and lower the risk of dementia.
Now, an international team of researchers has found more evidence that people also booze a lot less when taking these meds.
Advertisement
4 People booze a lot less when taking GLP-1 drugs like Ozempic, a new study out of Ireland found.
maeching – stock.adobe.com
'GLP-1 [drugs] have been shown to treat obesity and reduce the risk of multiple obesity-related complications,' said Professor Carel le Roux of University College Dublin in Ireland.
'The beneficial effects beyond obesity, such as on alcohol intake, are being actively studied, with some promising results.'
Advertisement
Le Roux's team analyzed data from 262 overweight or obese adults prescribed liraglutide or semaglutide for weight loss at a clinic in Dublin.
Semaglutide is sold as Ozempic to treat Type 2 diabetes and as Wegovy for obesity.
Saxenda and Victoza contain liraglutide. Saxenda is for weight loss, while Victoza is for diabetes.
4 Average alcohol intake in the study decreased from 11.3 to 4.3 drinks a week, a reduction of almost two-thirds.
European Association for the Study of Obesity
Advertisement
Volunteers reported their alcohol habits before the study began and were split into three groups — there were 31 non-drinkers, 52 rare drinkers (less than 10 drinks a week) and 179 regular drinkers (over 10 a week).
Most of the participants were female, the average age was 46 and the average weight was 216 pounds.
The researchers followed 188 of the 262 patients for an average of four months of treatment. None of the participants drank more than usual during that time.
Advertisement
Average alcohol intake decreased from 11.3 to 4.3 drinks a week, a reduction of almost two-thirds.
Among the regular drinkers, consumption declined from 23.2 to 7.8 drinks a week.
4 This graphic from the study shows the correlation between weight loss and alcohol reduction during treatment.
European Association for the Study of Obesity
The findings were published in January in the journal Diabetes, Obesity and Metabolism and are due to be presented in the coming days at the European Congress on Obesity in Malaga, Spain.
'The exact mechanism of how GLP-1 [drugs] reduce alcohol intake is still being investigated, but it is thought to involve curbing cravings for alcohol that arise in subcortical areas of the brain that are not under conscious control,' le Roux said. 'Thus, patients report the effects are 'effortless.''
Le Roux reported that the alcohol reduction from GLP-1s mirrors the results of nalmefene, a drug used to treat alcohol dependence in Europe.
4 Overconsumption of alcohol is a common problem worldwide. It's responsible for nearly 5% of deaths, statistics show.
Monkey Business – stock.adobe.com
Advertisement
Harmful alcohol use accounts for about 2.6 million deaths a year, 4.7% of all global deaths.
Treatment typically involves counseling, such as behavioral therapy, and medications that reduce the urge to drink. However, relapse rates are high.
GLP-1s are not a cure-all, to be sure. Side effects can include gastrointestinal issues like nausea, and less often, hair loss and skin pain. In very rare cases, blindness and behavioral changes can occur.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
12 hours ago
- New York Post
Ozempic penis: Male users reveal shocking change to their genitalia after injecting weight-loss shot
It's the miracle drug that promises to shrink your size — except where it matters. Male Ozempic users say their penises have gotten bigger since they started injecting the weight-loss shot, with dozens of well-endowed fellas flocking to online forums to fawn over their expanded members. 'I recently measured myself down there and noticed I gained about one inch,' an anonymous user recently claimed on a Reddit thread. Advertisement 'Now I think people will say it was because of the fat loss. However at the time I measured myself before (4 years ago), I was thinner,' the man claimed. 'I also bone pressed during measurement before and also this time. Has anyone else noticed this change in themselves?' 3 Male Ozempic users say their penises have gotten bigger since they started injecting the weight-loss shot, with dozens of well-endowed fellas flocking to online forums to fawn over their expanded members. Shutterstock / Andrey_Popov 'Yes,' another happy Redditor responded. 'I gained 1.5 inches in length. No joke. Like you I obviously know how long I was before I got very fat. Then after about seven months on Tirzepatide in my case I gained 1.5 inches in length. Definitely not all from weight loss.' Advertisement 'I noticed that happen to me as well,' a third man remarked. 'Yeah, wife has definitely noticed a difference, was 278lbs down to under 200 lbs,' an additional commenter claimed. Meanwhile, other men also claimed that they had noticed a size difference after taking Ozempic, but put it down to better blood flow and reduced fat around the pubic area. Advertisement Another Redditor responded saying the size difference was likely due to different external conditions during the before and after measurements. 'I feel like nobody is really reading what you are writing, that they blame the weight loss while you measured the first time when you were actually lighter,' the explained. 'Ozempic does not enlarge your penis, but an erect penis may change size considerably depending on time of day, temperature, and factors other than sexual arousal. So it's probably just simply that.' 3 Some men also admitted that they had noticed a size difference after taking Ozempic, but put it down to better blood flow and reduced fat around the pubic area. myskin – Advertisement 3 Since it became widely available across America in 2024, users have reported an array of unexpected side effects. K KStock – The phenonemon — dubbed 'Ozempic penis' or 'Ozemd**k' — is just the latest in a series of side effects users of the weight-loss drugs have allegedly experencied. 'Ozempic mouth' is another recently reported side effect, marked by pronounced folds at the corners of the mouth, noticeable wrinkles on the lips, and sagging skin along the lip contours and chin area Those alarmed by their changed appearance are now turning to cosmetic treatments – such as dermal fillers – to restore lost volume around the mouth area.
New York Post
13 hours ago
- New York Post
Weight loss drugs like Ozempic could mess with your birth control — and get you pregnant
A UK watchdog is urging women on GLP-1 weight-loss drugs like Ozempic and Mounjaro to use effective forms of birth control after receiving more than 40 pregnancy-related reports linked to the medications. The warning comes as women flood social media with stories of their so-called 'Ozempic babies' — including surprise pregnancies while on the pill. Trying to shed pounds, not grow a baby bump? Here's what you need to know about GLP-1s, pregnancy and the best contraception options to stay protected. 4 Studies show that at least one in eight US adults have tried GLP-1s. íÅí°íâ¬í¸í½í° íâíµí¼íµíËí°í¾ – What's in your GLP-1? Several GLP-1 drugs dominate the market, including Ozempic and Wegovy. Both contain semaglutide, an active ingredient that mimics a natural hormone in the body that boosts insulin production, slows digestion and curbs appetite. Then there's Saxenda and Victoza, powered by liraglutide, which functions in a similar way. Newer drugs like Mounjaro and Zepbound rely on tirzepatide, a key ingredient that targets a second hormone involved in appetite and blood sugar control. A surprise side effect While gastrointestinal symptoms like nausea, vomiting and diarrhea are common with GLP-1s, the surprise side effect making waves is unexpected pregnancy. The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has received 28 reports related to pregnancy in patients on tirzepatide, and nine each for semaglutide and liraglutide. 4 Women on tirzepatide-based GLP-1s should use barrier contraception. nenetus – In an alert this week, the agency warned that tirzepatide may reduce the effectiveness of oral contraceptives, especially in women with higher body weight. As a result, it recommended using barrier methods like condoms while on drugs like Mounjaro. So far, there's no evidence that GLP-1s affect non-oral birth control like IUDs, implants, patches, or rings, according to the UK's Faculty of Reproductive Healthcare. And yes, the advice applies even to women previously told they were infertile. GLP-1s have been shown to boost fertility by aiding weight loss, reducing inflammation and improving insulin sensitivity — leading some to conceive just months after starting treatment. 4 GLP-1 agonists can increase your fertility, but they can also interfere with pregnancy. Louis-Photo – Can you take GLP-1s while pregnant? Experts say no — at least not yet. There's not enough data to confirm whether GLP-1s are safe during pregnancy. While a some human studies suggests there is no harm in first-trimester use, testing in animals has shown the drugs could increase the risk of miscarriage and birth defects. 4 Scientists are still working to understand whether GLP-1s can negatively impact a developing fetus. Evrymmnt – Another reason to skip GLP-1s while pregnant: they suppress your appetite and can trigger gastrointestinal issues, which may lead to nutrient deficiencies that impact fetal development. The drugs should also be avoided during breastfeeding, since there's not enough research to confirm safety for infants. Trying to conceive? Here's the timeline If you're planning to get pregnant, the MHRA recommended stopping GLP-1s before you start trying to conceive and giving your body time to clear the drugs. For semaglutide users, that means quitting at least two months ahead. If you're on tirzepatide, stop one month before trying. Liraglutide clears the system faster, so you can stop right before you start trying to conceive.
Yahoo
17 hours ago
- Yahoo
Novo Nordisk Stock: Is It Still a Smart Buy?
This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran pharmaceutical company, however. 10 stocks we like better than Novo Nordisk › Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight loss drug Wegovy, have fallen nearly 18% in price since the start of this year. Popularity attracts competition, and investors are growing concerned that the Danish pharmaceutical giant won't be able to compete. I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, when Wegovy became the first GLP-1 drug specifically approved by the Food and Drug Administration (FDA) for that indication in mid-2021. Novo Nordisk's Ozempic was first, but it was used off-label as a weight-loss drug, and had only initially been approved as a diabetes treatment and kidney disease treatment. It's easy to believe in a company when it's riding high and unopposed. But late in 2023, a new entrant was approved -- mighty American pharmaceutical company Eli Lilly (NYSE: LLY) with its own GLP-1 treatment, Zepbound -- giving Novo Nordisk one of the strongest competitors imaginable. Almost certainly, this won't continue to be a two-car race for long. Other companies, both large and small, in the healthcare field are pushing hard to develop their own obesity drugs, with varying degrees of success. Eli Lilly alone is an intimidating presence. A mainstay on the American pharmaceutical scene, it's grown to a massive size, to the point where it's the most valuable pharmaceutical company in the world by market cap. It can leverage its vast resources to develop and market any kind of medicine it wants, and in the obesity segment, it was already nearly there with Zepbound's FDA-approved-for-diabetes sibling drug, Mounjaro. Since then, it seems Zepbound has carved out a significant market share from Wegovy. Precise figures are hard to come by, but according to a Goldman Sachs analysis recently reported by Barron's, Novo Nordisk is clinging to a 51% share of the roughly $28 billion market. Eli Lilly holds the rest. Like other pharmaceutical industry pundits, Goldman Sachs is predicting that once other obesity drugs are developed successfully and approved, the market will fragment. That's a wholly believable prediction given the zeal and urgency behind many of those efforts. Meanwhile, Novo Nordisk has taken a series of competitive blows that reduced its lead. A shortage of semaglutide -- the main ingredient of Wegovy -- led the FDA to allow compounding pharmacies to make copies of the molecule, essentially producing new competition. Although the shortage is officially over, it showed that Novo Nordisk would be vulnerable if such a situation reoccurred. Another of the numerous fresh setbacks was a head-to-head clinical trial conducted by Eli Lilly, pitting Zepbound against Wegovy. Last December, the results of the study indicated notably more significant weight loss for participants using Wegovy. One internal development also dented investor sentiment on Novo Nordisk, and that was the company's announcement in mid-May that long-serving CEO Lars Fruergaard Jørgensen was stepping down. When enterprises are humming along pleasantly, they rarely experience a top leader's departure. Novo Nordisk isn't just absorbing hurtful blows, though; it's been busy shoring up its defenses. As 2024 came to a close, it scooped up contract drug manufacturer Catalent, bringing Wegovy production more under its direct control. That $16.5 billion deal wasn't cheap by any yardstick, but if the new asset is managed well, it should be more than worth the cost ultimately. Novo Nordisk is also keeping up the pace with its own development activities, attempting to succeed with new medications and/or other indications for Wegovy. Its next-generation obesity treatment CagriSema was essentially a flop. However, the company has already had success winning FDA approval for the versatile Wegovy to treat liver disorder metabolic dysfunction-associated steatohepatitis (MASH), and it's developing the drug for a clutch of other ailments. It also has other medications for different disorders in its pipeline. Meanwhile, a score of researchers modeling the future of the obesity market feel that sales of such drugs will blast through the roof. Projections vary, but a typical one is the latest from Morgan Stanley. In May, the veteran investment bank upped its estimate for the market's peak (predicted to occur in 2035) to $150 billion, well up from its previous assumption of $105 billion. The former number is more than 6 times the $24 billion estimated sales of 2024. The very encouraging news for Novo Nordisk bulls like myself is that even if the market gets highly fragmented with numerous competing products and loses significantly more share -- unlikely, given its first-mover prominence and the strength of the Wegovy brand name -- it'll still be a player in a huge market. Yes, competition can be tough. There are a lot of prizes in this game, and more players are entering it. But I think this original player will manage to hold on and thrive, and I continue to consider Novo Nordisk stock a buy. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs Group. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Novo Nordisk Stock: Is It Still a Smart Buy? was originally published by The Motley Fool
